CN103732240A - G-csf二聚体在制备治疗神经退行性疾病药物中的应用 - Google Patents

G-csf二聚体在制备治疗神经退行性疾病药物中的应用 Download PDF

Info

Publication number
CN103732240A
CN103732240A CN201280036654.9A CN201280036654A CN103732240A CN 103732240 A CN103732240 A CN 103732240A CN 201280036654 A CN201280036654 A CN 201280036654A CN 103732240 A CN103732240 A CN 103732240A
Authority
CN
China
Prior art keywords
csf
dimers
colony stimulating
stimulating factor
dimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201280036654.9A
Other languages
English (en)
Other versions
CN103732240B (zh
Inventor
武栋栋
黄智华
黄予良
严孝强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yiyi biopharmaceutical (Beijing) Co.,Ltd.
Original Assignee
Generon Shanghai Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generon Shanghai Corp Ltd filed Critical Generon Shanghai Corp Ltd
Priority to CN201280036654.9A priority Critical patent/CN103732240B/zh
Publication of CN103732240A publication Critical patent/CN103732240A/zh
Application granted granted Critical
Publication of CN103732240B publication Critical patent/CN103732240B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明公开了G-CSF二聚体在制备治疗神经退行性疾病药物中的应用。本发明使用G-CSF二聚体分子，能够显著增加PD模型动物黑质多巴胺能神经元的数量，提高多巴胺能神经元的功能。此外，G-CSF二聚体分子能够显著减少海马区神经元细胞的凋亡，改善AD模型大鼠学习记忆能力。本发明的二聚体G-CSF的血清半衰期延长，有效阻止神经元的丢失，从而能够更有效地治疗神经退行性疾病。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN201280036654.9A 2011-07-25 2012-07-24 G-csf二聚体在制备治疗神经退行性疾病药物中的应用 Active CN103732240B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201280036654.9A CN103732240B (zh) 2011-07-25 2012-07-24 G-csf二聚体在制备治疗神经退行性疾病药物中的应用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201110209712 2011-07-25
CN201110209712.0 2011-07-25
CN201280036654.9A CN103732240B (zh) 2011-07-25 2012-07-24 G-csf二聚体在制备治疗神经退行性疾病药物中的应用
PCT/CN2012/079106 WO2013013613A1 (zh) 2011-07-25 2012-07-24 G-csf二聚体在制备治疗神经退行性疾病药物中的应用

Publications (2)

Publication Number Publication Date
CN103732240A true CN103732240A (zh) 2014-04-16
CN103732240B CN103732240B (zh) 2015-12-09

Family

ID=47600520

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280036654.9A Active CN103732240B (zh) 2011-07-25 2012-07-24 G-csf二聚体在制备治疗神经退行性疾病药物中的应用

Country Status (7)

Country Link
US (1) US9642917B2 (zh)
EP (1) EP2737905B1 (zh)
JP (1) JP5947891B2 (zh)
CN (1) CN103732240B (zh)
AU (1) AU2012289433B2 (zh)
CA (1) CA2842969C (zh)
WO (1) WO2013013613A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166219A (zh) * 2018-09-28 2021-07-23 纪念斯隆-凯特琳癌症中心 干细胞衍生的人小神经胶质细胞、制备方法及使用方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102260343A (zh) 2010-05-25 2011-11-30 健能隆医药技术（上海）有限公司 重组人g-csf二聚体在治疗神经损伤疾病中的用途
EP3050570A1 (en) * 2015-01-31 2016-08-03 Neurovision Pharma GmbH Pharmaceutical composition consisting of a combination of G-CSF with GM-CSF
US9876264B2 (en) 2015-10-02 2018-01-23 At&T Intellectual Property I, Lp Communication system, guided wave switch and methods for use therewith
WO2024037633A2 (en) 2022-08-19 2024-02-22 Evive Biotechnology (Shanghai) Ltd Formulations comprising g-csf and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036626A1 (en) * 2000-11-02 2002-05-10 Maxygen Aps Single-chain multimeric polypeptides

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3954004B2 (ja) 1991-12-26 2007-08-08 中外製薬株式会社 脳機能障害による疾患の予防・治療薬
FR2686900B1 (fr) 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
CA2212006A1 (en) 1995-02-03 1996-08-08 G.D. Searle & Co. Novel c-mpl ligands
US6551799B2 (en) 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6274710B1 (en) 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
CN1238367C (zh) 1998-10-26 2006-01-25 路德维格癌症研究院 分离的编码t细胞诱导因子(tif)的核酸分子,其编码蛋白及其应用
US7307161B1 (en) 1999-04-28 2007-12-11 Genetics Institute, Llc Human Gil-19/AE289 polynucleotides
EP1200124B1 (en) 1999-07-13 2008-09-10 Bolder Biotechnology, Inc. Erythropoietin-immunoglobulin fusion proteins
GB0024442D0 (en) 2000-10-05 2000-11-22 Isis Innovation Genetic factors affecting the outcome of viral infections
US20020142964A1 (en) 2000-11-02 2002-10-03 Nissen Torben Lauesgaard Single-chain polypeptides
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
US6797493B2 (en) 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
EP1572936A2 (en) 2002-03-05 2005-09-14 Eli Lilly And Company Heterologous g-csf fusion proteins
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
EP1817047B1 (en) 2004-11-05 2012-02-08 Northwestern University Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders
CN100515491C (zh) 2005-01-04 2009-07-22 健能隆医药技术（上海）有限公司 白介素-22的医药用途
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
US7723302B2 (en) 2007-05-01 2010-05-25 Florida Atlantic University Method of treating Parkinson's disease
WO2008147534A1 (en) 2007-05-22 2008-12-04 Maxygen Holdings Ltd. Method for the treatment of neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (g-csf) variant
EP3173484B1 (en) 2007-05-30 2018-09-26 Postech Academy-Industry- Foundation Immunoglobulin fusion proteins
WO2009019441A2 (en) 2007-08-03 2009-02-12 Asterion Limited Granulocyte colony stimulating factor
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
AU2008323770B2 (en) 2007-11-07 2014-08-07 Genentech, Inc. Compositions and methods for treatment of microbial disorders
UA118536C2 (uk) 2008-07-23 2019-02-11 Амбркс, Інк. Модифікований поліпептид бичачого гранулоцитарного колонієстимулювального фактора та його застосування
US20130121959A1 (en) 2010-01-13 2013-05-16 Joseph R. Maxwell Il-22-fc and hepcidin activity
LT2010013A (lt) 2010-02-10 2011-08-25 Uab Profarma, , Biologiškai aktyvių granulocitų kolonijas stimuliuojančio faktoriaus darinių išskyrimo ir gryninimo būdas
LT2010012A (lt) 2010-02-10 2011-08-25 Uab Profarma, , Granulocitus stimuliuojančio baltymo linijiniai oligomerai su prailginta in vivo gyvavimo trukme
CN102260343A (zh) * 2010-05-25 2011-11-30 健能隆医药技术（上海）有限公司 重组人g-csf二聚体在治疗神经损伤疾病中的用途
CN102380090A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 G-csf二聚体在治疗嗜中性粒细胞减少症中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036626A1 (en) * 2000-11-02 2002-05-10 Maxygen Aps Single-chain multimeric polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHIJIE SONG ET AL.: "Granulocyte-colony stimulating factor (G-CSF) enhances recovery in mouse model of parkinson"s disease", 《NEUROSCIENCE LETTER》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166219A (zh) * 2018-09-28 2021-07-23 纪念斯隆-凯特琳癌症中心 干细胞衍生的人小神经胶质细胞、制备方法及使用方法

Also Published As

Publication number Publication date
CA2842969C (en) 2018-03-27
WO2013013613A1 (zh) 2013-01-31
JP2014521612A (ja) 2014-08-28
US9642917B2 (en) 2017-05-09
AU2012289433B2 (en) 2017-07-27
EP2737905B1 (en) 2019-09-11
AU2012289433A1 (en) 2014-03-13
US20140248234A1 (en) 2014-09-04
CA2842969A1 (en) 2013-01-31
CN103732240B (zh) 2015-12-09
EP2737905A1 (en) 2014-06-04
EP2737905A4 (en) 2015-03-18
JP5947891B2 (ja) 2016-07-06

Similar Documents

Publication Publication Date Title
CN104066440B (zh) 白介素-22在治疗和预防神经损伤疾病或神经退行性疾病中的用途
JP6114186B2 (ja) 組換えヒトｇ−ｃｓｆ二量体およびその神経系疾患の治療における用途
CN103732240A (zh) G-csf二聚体在制备治疗神经退行性疾病药物中的应用
CN104974262B (zh) 重组双功能融合蛋白及其制法和用途
JP2004099471A (ja) 心筋梗塞および心不全の治療薬
US6486122B1 (en) Methods of increasing body weight in a subject by administering TGF-α
EP1897441A1 (en) TGF-alpha polypeptides, functional fragments and methods of use therefor
CN108727484A (zh) 人血清淀粉样蛋白a1功能性短肽及其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20200611

Address after: 101111 1st, 2nd and 3rd floors, 3rd floor, 99 Kechuang 14th Street, Daxing District, Beijing Economic and Technological Development Zone

Patentee after: Beijing Jiannenglong Biopharmaceutical Co.,Ltd.

Address before: 201203 Shanghai City, Pudong New Area Road No. 1011, room 307, Zhangjiang hi tech Haley

Patentee before: GENERON (SHANGHAI) Corp.,Ltd.

TR01 Transfer of patent right
CP01 Change in the name or title of a patent holder

Address after: 101111 1st, 2nd and 3rd floors, 3rd floor, 99 Kechuang 14th Street, Daxing District, Beijing Economic and Technological Development Zone

Patentee after: Yiyi biopharmaceutical (Beijing) Co.,Ltd.

Address before: 101111 1st, 2nd and 3rd floors, 3rd floor, 99 Kechuang 14th Street, Daxing District, Beijing Economic and Technological Development Zone

Patentee before: Beijing Jiannenglong Biopharmaceutical Co.,Ltd.

CP01 Change in the name or title of a patent holder
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20140416

Assignee: NANJING SHUNXIN PHARMACEUTICALS CO., LTD. OF CHIATAI TIANQING PHARMACEUTICAL Group

Assignor: Yiyi biopharmaceutical (Beijing) Co.,Ltd.

Contract record no.: X2022990000878

Denomination of invention: Application of G-CSF Dimer in Preparation of Drugs for Neurodegenerative Diseases

Granted publication date: 20151209

License type: Exclusive License

Record date: 20221102

EE01 Entry into force of recordation of patent licensing contract